Pacific Shuanglin Bio-pharmacy Co., Ltd. (SHE:000403)

China · Delayed Price · Currency is CNY

9.67

+0.30 (3.20%)

Oct 23, 2026, 1:45 PM CST

Market Cap	9.07B -41.3%
Revenue (ttm)	2.42B +1.5%
Net Income	212.39M -62.1%
EPS	0.22 -62.3%
Shares Out	937.54M
PE Ratio	43.37
Forward PE	11.13
Dividend	0.30 (3.10%)
Ex-Dividend Date	Oct 23, 2026

Volume	5,639,290
Open	9.70
Previous Close	9.37
Day's Range	9.31 - 9.70
52-Week Range	8.54 - 16.42
Beta	0.43
Analysts	Strong Buy
Price Target	19.25 (+99.07%)
Earnings Date	Oct 22, 2026

About SHE:000403

Pacific Shuanglin Bio-pharmacy Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of blood products in China and internationally. The company offers human serum albumin, human immunoglobulin (PH4), human immunoglobulin, hepatitis B human immunoglobulin, tetanus immunoglobulin, rabies immunoglobulin, human coagulation factor VIII, human fibrinogen, lyophilized intravenous immunoglobulin (pH4), hepatitis B immunoglobulin (pH4), and human prothrombin complex concentrate, as well as intravenous cyt... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1993

Employees 2,755

Stock Exchange Shenzhen Stock Exchange

Ticker Symbol 000403

Full Company Profile

Financial Performance

In 2025, SHE:000403's revenue was 2.63 billion, a decrease of -0.83% compared to the previous year's 2.65 billion. Earnings were 419.27 million, a decrease of -43.75%.

Financial Statements

Analyst Summary

According to 2 analysts, the average rating for 000403 stock is "Strong Buy." The 12-month stock price target is ¥19.25, which is an increase of 99.07% from the latest price.

Price Target

¥19.25

(99.07% upside)

Analyst Consensus: Strong Buy

Stock Forecasts